FIELD: medicine.
SUBSTANCE: present invention refers to immunology and biotechnology. What is presented is an IL-1β-binding antibody or its IL-1β-binding fragment containing V heavy and light chain regions. The above antibody binds to human IL-1β with dissociation constant less than 1pM. Versions of the antibody are described. There are disclosed corresponding coding nucleic acids (NA), as well as: a NA passage vector to a host cell, the host cell producing a coded polypeptide. What is described is using the antibody for preparing the other format of the above antibody: "camel-like", VHH antibody, nanobody. What is disclosed is a pharmaceutical composition for treating or preventing an IL-1β-related disease in a mammal on the basis of the antibody, as well as a method of treating or preventing the IL-1β-related disease in a mammal.
EFFECT: using the invention provides the novel IL-1β-specific antibodies with high IL-1β affinity that can find application in medicine for preventing, treating the diseases mediated by IL-1β activity.
39 cl, 20 dwg, 6 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-1R1 BINDING MEMBERS | 2009 |
|
RU2555532C2 |
| ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | 2015 |
|
RU2693084C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| ANTIBODIES DIRECTED AGAINST IL-17 | 2011 |
|
RU2595385C2 |
| ANTIBODY THAT BINDS TO VEGF AND IL-1BETA, AND METHODS OF USE THEREOF | 2019 |
|
RU2816476C2 |
| HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2581812C2 |
| IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
| HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN IL-4 RECEPTORS | 2009 |
|
RU2539774C2 |
| HIGH-AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | 2014 |
|
RU2663106C2 |
